Curative resection of pancreatic ductal adenocarcinoma developing in the remnant pancreas 13 years after distal pancreatectomy for intraductal papillary mucinous neoplasms: A case report

• Published in: Molecular and clinical oncology Vol. 8; no. 3; pp. 417 - 420
• Main Authors: Einama, Takahiro, Kamachi, Hirofumi, Sakata, Toshihiro, Shibata, Kengo, Wakizaka, Kazuki, Sugiyama, Ko, Shibuya, Kazuaki, Shimada, Shingo, Wakayama, Kenji, Orimo, Tatsuya, Yokoo, Hideki, Kamiyama, Toshiya, Mitsuhashi, Tomoko, Taketomi, Akinobu
• Format: Journal Article
• Language: English
• Published: England Spandidos Publications 01.03.2018; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Antigens; Blood; Care and treatment; Case reports; Development and progression; Excision (Surgery); Laboratories; Medical imaging; Methods; NMR; Nuclear magnetic resonance; Oncology; Pancreas; Pancreatectomy; Pancreatic cancer; Patient outcomes; Patients; Surgery; Surveillance; Tumors; Japan; remnant pancreas; intraductal papillary mucinous neoplasms; pancreatic ductal adenocarcinoma
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2018.1556

Intraductal papillary mucinous neoplasms (IPMNs) are characterized by the papillary proliferation of atypical mucinous epithelial cells in the pancreatic ductal system. There are two recurrence patterns following resection of IPMNs: Metachronous multifocal occurrence of IPMNs, and distinct pancreatic ductal adenocarcinoma (PDAC) in the remnant pancreas. Several recent studies investigated the development of distinct PDAC during follow-up evaluation of IPMNs and the incidence rate ranged from 4.5 to 8%. Thus, IMPNs may be a good predictor for the early detection of PDAC during observation or after the resection of IPMNs. We herein report the rare case of a patient who underwent resection of PDAC that developed in the remnant pancreas 13 years after distal pancreatectomy with splenectomy for IPMNs. PDAC may develop in the remnant pancreas after pancreatectomy for IPMNs; thus, careful long-term follow-up with periodic surveillance, at least every 6 months, is warranted.